Skip to main
LSTA
LSTA logo

LSTA Stock Forecast & Price Target

LSTA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lisata Therapeutics Inc. is experiencing promising developments in its investigational product, certepetide, which has demonstrated a positive trend in overall survival, as indicated by preliminary data from ASCO GI. The company has reported notable results from Cohort A, highlighting four complete responses in the certepetide group, and further data from Cohort B suggests that a second dose may enhance progression-free survival (PFS) and overall response rate (ORR) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). As a clinical-stage pharmaceutical company focused on delivering innovative therapies for solid tumors, Lisata's advancements in certepetide position it favorably within the pharmaceutical landscape, contributing to a positive outlook for its stock.

Bears say

Lisata Therapeutics Inc. faces significant risks that could negatively impact its stock, primarily due to the potential for failed or inconclusive clinical trials related to its investigational product, certepetide. Additionally, the company's ability to secure sufficient funding to advance its drug development is a critical concern that raises uncertainty about future growth prospects. Overall, the combination of these clinical and financial challenges contributes to a negative outlook on the company’s stock performance.

LSTA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lisata Therapeutics Inc (LSTA) Forecast

Analysts have given LSTA a Strong Buy based on their latest research and market trends.

According to 2 analysts, LSTA has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lisata Therapeutics Inc (LSTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.